Folic Acid

Folic Acid

SCHEMBL182653

Nc1nc2ncc(CNc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1.O=C1CCC(=O)N1O

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMS P04818 2/20 0.87
KDM4E B2RXH2 1/20 0.87
MEN1 O00255 1/20 0.87
ALDH1A1 P00352 1/20 0.87
POLB P06746 1/20 0.87
GAA P10253 1/20 0.87
AKR1B1 P15121 1/20 0.87
HPGD P15428 1/20 0.87
TSHR P16473 1/20 0.87
PTGS2 P35354 1/20 0.87
KMT2A Q03164 1/20 0.87
HSD17B10 Q99714 1/20 0.87
TDP1 Q9NUW8 1/20 0.87
ADORA3 P0DMS8 1/20 0.65
DHFR P00374 5/20 0.59
ATIC P31939 3/20 0.59
GART P22102 2/20 0.59
MTHFD1 P11586 1/20 0.51
MTHFD2 P13995 1/20 0.51
SOST Q9BQB4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Folic Acid SCHEMBL27970859 0.96 TYMS (0.82) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL28212675 0.93 TYMS (0.85) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29349485 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29441959 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29357550 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29624885 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL3877 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL248712 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL16492117 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL332170 0.93 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210128516-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO NOVARTIS AG (CH) 2021-05-06 US disclosed
EP-3332811-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING COVALENTLY ATTACHED CAMPTOTHECIN Cerulean Pharma Inc. (US) 2018-06-13 EP disclosed
EP-2402036-B1 Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto CERULEAN PHARMA INC (US) 2018-02-14 EP disclosed
US-20170369651-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO INSERT THERAPEUTICS, INC. 2017-12-28 US disclosed
US-9550860-B2 Cyclodextrin-based polymers for therapeutics delivery CERULEAN PHARMA INC. (US) 2017-01-24 US disclosed
US-20150165055-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO CERULEAN PHARMA INC. (US) 2015-06-18 US disclosed
US-20140288023-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY CERULEAN PHARMA INC. (US) 2014-09-25 US disclosed
US-8680202-B2 Cyclodextrin-based polymers for therapeutics delivery CERULEAN PHARMA INC. (US) 2014-03-25 US disclosed
US-20140044669-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY CERULEAN PHARMA INC. (US) 2014-02-13 US disclosed
US-8609081-B2 Cyclodextrin-based polymers for therapeutics delivery CERULEAN PHARMA INC. (US) 2013-12-17 US disclosed
US-20090169478-A1 In Vivo Imaging and Therapy with Magnetic Nanoparticle Conjugates BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) 2009-07-02 US disclosed
EP-1901762-A2 USE OF ONE OR MORE METAL CARRIERS TO SELECTIVELY KILL MAMMALIAN CELLS Cancure Laboratories, LLC (US) 2008-03-26 EP disclosed
US-20080058427-A1 Cyclodextrin-based polymers for therapeutics delivery INSERT THERAPEUTICS, INC. (US) 2008-03-06 US disclosed
EP-1855725-A2 CYCLODEXTRIN-BASED POLYMERS CONTAINING PHOTOCLEAVABLE LINKERS FOR DRUG DELIVERY Insert Therapeutics Inc. (US) 2007-11-21 EP disclosed
US-7270808-B2 Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity INSERT THERAPEUTICS, INC. (US) 2007-09-18 US disclosed
WO-2007008376-A2 USE OF ONE OR MORE METAL CARRIERS TO SELECTIVELY KILL MAMMALIAN CELLS CANCURE LABORATORIES, LLC (US) 2007-01-18 WO disclosed
US-20070010427-A1 Use of one or more metal carriers to selectively kill mammalian cells CANCURE LABORATORIES, LLC (US) 2007-01-11 US disclosed
US-20060210527-A1 Cyclodextrin-based polymers for therapeutics delivery INSERT THERAPEUTICS, INC. (US) 2006-09-21 US disclosed
WO-2006089007-A2 CYCLODEXTRIN-BASED POLYMERS CONTAINING PHOTOCLEAVABLE LINKERS FOR DRUG DELIVERY INSERT THERAPEUTICS, INC. (US) 2006-08-24 WO disclosed
US-20040077595-A1 Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity INSERT THERAPEUTICS, INC. (US) 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058427-A1 Cyclodextrin-based polymers for therapeutics delivery DDOST, DSC1, SI TYMS 1005/4885KDM4E 3582/4885MEN1 4082/4885
US-20210128516-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO SDCBP, DDOST, CD47 TYMS 1034/4885KDM4E 3113/4885MEN1 4023/4885
US-20140044669-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY DDOST, DSC1, SI TYMS 1005/4885KDM4E 3582/4885MEN1 4082/4885
US-20040077595-A1 Having covalently coupled bioactive agent and targeting ligand; controlled release; stability, solubility; reduced toxicity CD40, TNFSF11, TNFSF10 TYMS 3053/4885KDM4E 4241/4885MEN1 3956/4885
US-20060210527-A1 Cyclodextrin-based polymers for therapeutics delivery SI, PAICS, DSC1 TYMS 421/4885KDM4E 3629/4885MEN1 3718/4885
US-20140288023-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY DDOST, DSC1, SI TYMS 1005/4885KDM4E 3582/4885MEN1 4082/4885
US-20150165055-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO SDCBP, DDOST, CD47 TYMS 1034/4885KDM4E 3113/4885MEN1 4023/4885
US-20170369651-A1 CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO SDCBP, DDOST, CD47 TYMS 1034/4885KDM4E 3113/4885MEN1 4023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.